This presentation explores innovative approaches to treating triple-negative breast cancer (TNBC), addressing the limitations of traditional anthracycline regimens and evaluating evidence for alternative treatments. Objectives include assessing efficacy, minimising toxicity, and tailoring post-surgery strategies. The study details a Phase II single-arm trial, outlining participant criteria and the treatment phases. Comprehensive evaluations focus on tumour assessments, imaging, biomarkers,...